Coherus Biosciences Stock Price, News & Analysis (NASDAQ:CHRS)

$9.55 +0.40 (+4.37 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$9.55
Today's Range$9.05 - $9.65
52-Week Range$8.05 - $26.55
Volume343,552 shs
Average Volume456,632 shs
Market Capitalization$547.54 million
P/E Ratio-1.76
Dividend YieldN/A
Beta3.81

About Coherus Biosciences (NASDAQ:CHRS)

Coherus Biosciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Debt-to-Equity Ratio1.84%
Current Ratio5.46%
Quick Ratio5.46%

Price-To-Earnings

Trailing P/E Ratio-1.7619893690233
Forward P/E Ratio-2.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$190.11 million
Price / Sales3.01
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book21.70

Profitability

Trailing EPS($5.42)
Net Income$-127,330,000.00
Net Margins-73.89%
Return on Equity-582.31%
Return on Assets-138.04%

Miscellaneous

Employees152
Outstanding Shares59,840,000

Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) posted its earnings results on Monday, November, 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.26. Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. View Coherus Biosciences' Earnings History.

When will Coherus Biosciences make its next earnings announcement?

Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Coherus Biosciences.

Where is Coherus Biosciences' stock going? Where will Coherus Biosciences' stock price be in 2018?

8 equities research analysts have issued 12-month price targets for Coherus Biosciences' stock. Their predictions range from $17.00 to $46.00. On average, they expect Coherus Biosciences' stock price to reach $32.00 in the next year. View Analyst Ratings for Coherus Biosciences.

What are Wall Street analysts saying about Coherus Biosciences stock?

Here are some recent quotes from research analysts about Coherus Biosciences stock:

  • 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (1/9/2018)
  • 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)
  • 3. Credit Suisse Group AG analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)

Who are some of Coherus Biosciences' key competitors?

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the folowing people:

  • Dennis M. Lanfear, Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Jean-Frederic Viret Ph.D., Chief Financial Officer (Age 51)
  • Peter K. Watler, Chief Technology Officer (Age 55)
  • Alan C. Herman Ph.D., Chief Scientific Officer (Age 69)
  • Barbara K. Finck M.D., Chief Medical Officer (Age 69)
  • Mats Wahlstrom, Lead Independent Director (Age 63)
  • Christos Richards, Director (Age 59)
  • August J. Troendle M.D., Director (Age 60)
  • James I. Healy M.D. Ph.D., Independent Director (Age 52)
  • V. Bryan Lawlis Jr. Ph.D., Independent Director (Age 65)

Who owns Coherus Biosciences stock?

Coherus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.35%), Citadel Advisors LLC (2.96%), UBS Asset Management Americas Inc. (2.33%), TIAA CREF Investment Management LLC (1.74%), State of Wisconsin Investment Board (1.54%) and Millennium Management LLC (1.16%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus Biosciences.

Who sold Coherus Biosciences stock? Who is selling Coherus Biosciences stock?

Coherus Biosciences' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Candriam Luxembourg S.C.A., C WorldWide Group Holding A S, Teachers Retirement System of The State of Kentucky, Rock Springs Capital Management LP, Bank of New York Mellon Corp and Rhumbline Advisers. View Insider Buying and Selling for Coherus Biosciences.

Who bought Coherus Biosciences stock? Who is buying Coherus Biosciences stock?

Coherus Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Millennium Management LLC, State of Wisconsin Investment Board, Deutsche Bank AG, Goldman Sachs Group Inc., Macquarie Group Ltd., UBS Asset Management Americas Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Coherus Biosciences.

How do I buy Coherus Biosciences stock?

Shares of Coherus Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of Coherus Biosciences stock can currently be purchased for approximately $9.55.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $547.54 million and generates $190.11 million in revenue each year. The biotechnology company earns $-127,330,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Coherus Biosciences employs 152 workers across the globe.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus Biosciences (CHRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Coherus Biosciences (NASDAQ:CHRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.00$32.00$32.00$37.00
Price Target Upside: 161.22% upside161.22% upside161.22% upside196.00% upside

Coherus Biosciences (NASDAQ:CHRS) Consensus Price Target History

Price Target History for Coherus Biosciences (NASDAQ:CHRS)

Coherus Biosciences (NASDAQ:CHRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017CitigroupReiterated RatingBuy$23.00N/AView Rating Details
9/27/2017Credit Suisse GroupReiterated RatingOutperform$24.00 -> $17.00LowView Rating Details
9/8/2017CowenReiterated RatingOutperform$45.00LowView Rating Details
9/8/2017Maxim GroupReiterated RatingBuy$40.00 -> $20.00HighView Rating Details
8/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight -> Overweight$32.00 -> $25.00LowView Rating Details
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 -> $43.00HighView Rating Details
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 -> $37.00HighView Rating Details
5/21/2017BarclaysReiterated RatingOverweight$46.00HighView Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Coherus Biosciences (NASDAQ:CHRS) Earnings History and Estimates Chart

Earnings by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Coherus Biosciences (NASDAQ CHRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018N/AView Earnings Details
11/6/2017Q3 2017($0.83)($1.09)ViewN/AView Earnings Details
8/7/2017Q2 2017($1.29)($1.08)$1.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.54)($1.54)$0.16 millionViewListenView Earnings Details
3/13/2017Q4 2016($1.11)($1.71)$10.00 million$0.84 millionViewListenView Earnings Details
11/9/2016Q3 2016($1.56)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)$12.36 millionViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)$8.63 million$10.20 millionViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 million$6.87 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 million$5.81 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Coherus Biosciences (NASDAQ:CHRS) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.39 EPS
Next Year EPS Consensus Estimate: $-2.9 EPS

Dividends

Dividend History for Coherus Biosciences (NASDAQ:CHRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Coherus Biosciences (NASDAQ CHRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.28%
Institutional Ownership Percentage: 82.46%
Insider Trades by Quarter for Coherus Biosciences (NASDAQ:CHRS)
Institutional Ownership by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Coherus Biosciences (NASDAQ CHRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/8/2017Alan C HermanInsiderSell17,535$15.02$263,375.7049,651View SEC Filing  
7/5/2017Alan C HermanInsiderSell600$15.00$9,000.0067,186View SEC Filing  
4/3/2017Alan C HermanInsiderSell11,333$20.73$234,933.0990,452View SEC Filing  
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.006,892View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.006,225View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20143,917View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.006,225View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77161,687View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.006,225View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.0071,635View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.0071,635View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82186,782View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.833,991View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.8250,000View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50198,115View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50202,365View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00207,167View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00221,615View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17211,865View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.0063,836View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36214,699View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00214,699View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87214,699View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Coherus Biosciences (NASDAQ CHRS) News Headlines

Source:
DateHeadline
Analyzing Coherus Biosciences (CHRS) & Cidara Therapeutics (CDTX)Analyzing Coherus Biosciences (CHRS) & Cidara Therapeutics (CDTX)
www.americanbankingnews.com - February 17 at 1:16 AM
Coherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by BrokeragesCoherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 1:54 PM
 Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - February 12 at 10:46 AM
AbSci Appoints Alan Herman, PhD to Scientific Advisory BoardAbSci Appoints Alan Herman, PhD to Scientific Advisory Board
finance.yahoo.com - February 5 at 3:24 PM
BidaskClub Lowers Coherus Biosciences (CHRS) to SellBidaskClub Lowers Coherus Biosciences (CHRS) to Sell
www.americanbankingnews.com - February 3 at 1:28 PM
Coherus Biosciences (CHRS) Downgraded by BidaskClub to "Hold"Coherus Biosciences (CHRS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - January 28 at 10:00 AM
Coherus Biosciences Target of Unusually Large Options Trading (CHRS)Coherus Biosciences Target of Unusually Large Options Trading (CHRS)
www.americanbankingnews.com - January 25 at 1:52 AM
How a federal rule change helps this Peninsula drug company be masters of our own domain - San Francisco Business TimesHow a federal rule change helps this Peninsula drug company be 'masters of our own domain' - San Francisco Business Times
www.bizjournals.com - January 24 at 3:28 PM
Coherus Biosciences Inc (CHRS) Given Average Rating of "Buy" by AnalystsCoherus Biosciences Inc (CHRS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 20 at 1:40 PM
Cramer reveals the biggest winners and losers from the JP...Cramer reveals the biggest winners and losers from the JP...
finance.yahoo.com - January 17 at 9:26 AM
Five Rules for This Market Beast: Cramers Mad Money Recap (Tues 1/16/18)Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
finance.yahoo.com - January 17 at 9:26 AM
Winners & losers from JP Morgan Healthcare ConferenceWinners & losers from JP Morgan Healthcare Conference
finance.yahoo.com - January 17 at 9:26 AM
Coherus Biosciences (CHRS) Rating Increased to Buy at BidaskClubCoherus Biosciences (CHRS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 13 at 5:38 PM
Coherus Biosciences (CHRS) Rating Lowered to Hold at Zacks Investment ResearchCoherus Biosciences (CHRS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM
 Brokerages Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share Brokerages Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - January 9 at 9:38 AM
Coherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar ... - StreetInsider.comCoherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar ... - StreetInsider.com
www.streetinsider.com - January 7 at 10:48 PM
Coherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar Candidate Granting Type 2 MeetingCoherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar Candidate Granting Type 2 Meeting
www.streetinsider.com - January 6 at 9:36 AM
Coherus Biosciences (CHRS) Upgraded by Zacks Investment Research to "Buy"Coherus Biosciences (CHRS) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 3 at 10:02 PM
Coherus Biosciences (CHRS) Rating Increased to Sell at ValuEngineCoherus Biosciences (CHRS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - January 3 at 9:22 PM
Coherus BioSciences Management to Present at The 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Coherus BioSciences Management to Present at The 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 6:34 PM
Coherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare ConferenceCoherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:32 AM
ETFs with exposure to Coherus BioSciences, Inc. : December 27, 2017ETFs with exposure to Coherus BioSciences, Inc. : December 27, 2017
finance.yahoo.com - December 28 at 11:27 AM
Coherus Biosciences Inc (CHRS) Receives Consensus Recommendation of "Buy" from AnalystsCoherus Biosciences Inc (CHRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 26 at 2:38 PM
Coherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.90 Per ShareCoherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - December 23 at 11:22 PM
-$0.90 Earnings Per Share Expected for Coherus Biosciences Inc (CHRS) This Quarter-$0.90 Earnings Per Share Expected for Coherus Biosciences Inc (CHRS) This Quarter
www.americanbankingnews.com - December 23 at 11:18 PM
Coherus Biosciences (CHRS) Rating Increased to Hold at BidaskClubCoherus Biosciences (CHRS) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 22 at 11:28 PM
-$0.90 EPS Expected for Coherus Biosciences Inc (CHRS) This Quarter-$0.90 EPS Expected for Coherus Biosciences Inc (CHRS) This Quarter
www.americanbankingnews.com - December 6 at 5:36 AM
Coherus BioSciences, Inc. (CHRS) Receives Average Recommendation of "Hold" from AnalystsCoherus BioSciences, Inc. (CHRS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 1 at 7:49 PM
Coherus BioSciences Management to Present at BMO’s Prescriptions for Success Healthcare ConferenceCoherus BioSciences Management to Present at BMO’s Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 1 at 4:56 PM
Trade of the Day: Coherus Biosciences Inc (CHRS)Trade of the Day: Coherus Biosciences Inc (CHRS)
finance.yahoo.com - November 25 at 10:48 AM
Stock Traders Purchase Large Volume of Put Options on Coherus BioSciences (CHRS)Stock Traders Purchase Large Volume of Put Options on Coherus BioSciences (CHRS)
www.americanbankingnews.com - November 23 at 1:36 AM
-$0.90 EPS Expected for Coherus BioSciences, Inc. (CHRS) This Quarter-$0.90 EPS Expected for Coherus BioSciences, Inc. (CHRS) This Quarter
www.americanbankingnews.com - November 18 at 9:14 AM
Trade of the Day: Coherus Biosciences Inc (CHRS) - Investorplace.comTrade of the Day: Coherus Biosciences Inc (CHRS) - Investorplace.com
investorplace.com - November 17 at 2:24 PM
ValuEngine Lowers Coherus BioSciences, Inc. (CHRS) to Strong SellValuEngine Lowers Coherus BioSciences, Inc. (CHRS) to Strong Sell
www.americanbankingnews.com - November 11 at 7:00 PM
Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results - GlobeNewswire (press release)Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 8:13 PM
Edited Transcript of CHRS earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of CHRS earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 8:12 PM
Coherus BioSciences, Inc. (CHRS) Releases  Earnings ResultsCoherus BioSciences, Inc. (CHRS) Releases Earnings Results
www.americanbankingnews.com - November 7 at 10:09 AM
Coherus BioSciences Reports Third Quarter 2017 Operating and Financial ResultsCoherus BioSciences Reports Third Quarter 2017 Operating and Financial Results
finance.yahoo.com - November 6 at 6:22 PM
Coherus BioSciences reports 3Q lossCoherus BioSciences reports 3Q loss
finance.yahoo.com - November 6 at 6:22 PM
Coherus BioSciences, Inc. (CHRS) Receives Average Rating of "Buy" from AnalystsCoherus BioSciences, Inc. (CHRS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 3:58 PM
Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference - GlobeNewswire (press release)Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 1 at 5:57 PM
Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare ConferenceCoherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference
finance.yahoo.com - November 1 at 5:57 PM
Coherus BioSciences, Inc. (CHRS) Scheduled to Post Quarterly Earnings on TuesdayCoherus BioSciences, Inc. (CHRS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
-$1.05 Earnings Per Share Expected for Coherus BioSciences, Inc. (CHRS) This Quarter-$1.05 Earnings Per Share Expected for Coherus BioSciences, Inc. (CHRS) This Quarter
www.americanbankingnews.com - October 28 at 7:28 PM
Coherus BioSciences Is Now Oversold (CHRS)Coherus BioSciences Is Now Oversold (CHRS)
www.thestreet.com - October 26 at 5:26 PM
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : October 24, 2017Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : October 24, 2017
finance.yahoo.com - October 24 at 7:32 PM
Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th - GlobeNewswire (press release)Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th - GlobeNewswire (press release)
globenewswire.com - October 23 at 5:46 PM
Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6thCoherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th
finance.yahoo.com - October 23 at 5:46 PM
ETFs with exposure to Coherus BioSciences, Inc. : October 20, 2017ETFs with exposure to Coherus BioSciences, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 3:37 PM
Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols - PR Newswire (press release)Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols - PR Newswire (press release)
www.prnewswire.com - October 19 at 3:59 PM

SEC Filings

Coherus Biosciences (NASDAQ:CHRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Coherus Biosciences (NASDAQ:CHRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Coherus Biosciences (NASDAQ CHRS) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.